Cargando…
Prognostic value of (18)F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis
PURPOSE: This study aimed to investigate the value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in predicting early immunotherapy response of immune checkpoint inhibitors (ICIs) in patients with advanced or metastatic non-small-cell lung cancer (NSC...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713836/ https://www.ncbi.nlm.nih.gov/pubmed/36466905 http://dx.doi.org/10.3389/fimmu.2022.1014063 |
_version_ | 1784842098411831296 |
---|---|
author | Ling, Tao Zhang, Lianghui Peng, Rui Yue, Chao Huang, Lingli |
author_facet | Ling, Tao Zhang, Lianghui Peng, Rui Yue, Chao Huang, Lingli |
author_sort | Ling, Tao |
collection | PubMed |
description | PURPOSE: This study aimed to investigate the value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in predicting early immunotherapy response of immune checkpoint inhibitors (ICIs) in patients with advanced or metastatic non-small-cell lung cancer (NSCLC). METHODS: A comprehensive search of PubMed, Web of science, Embase and the Cochrane library was performed to examine the prognostic value of (18)F-FDG PET/CT in predicting early immunotherapy response of ICIs in patients with NSCLC. The main outcomes for evaluation were overall survival (OS) and progression-free survival (PFS). Detailed data from each study were extracted and analyzed using STATA 14.0 software. RESULTS: 13 eligible articles were included in this systematic review. Compared to baseline (18)F-FDG PET/CT imaging, the pooled hazard ratios (HR) of maximum and mean standardized uptake values SUV(max), SUV(mean), MTV and TLG for OS were 0.88 (95% CI: 0.69-1.12), 0.79 (95% CI: 0.50-1.27), 2.10 (95% CI: 1.57-2.82) and 1.58 (95% CI: 1.03-2.44), respectively. The pooled HR of SUV(max), SUV(mean), MTV and TLG for PFS were 1.06 (95% CI: 0.68–1.65), 0.66 (95% CI: 0.48-0.90), 1.50 (95% CI: 1.26-1.79), 1.27 (95% CI: 0.92-1.77), respectively. Subgroup analysis showed that high MTV group had shorter OS than low MTV group in both first line group (HR: 1.97, 95% CI: 1.39-2.79) and undefined line group (HR: 2.11, 95% CI: 1.61-2.77). High MTV group also showed a shorter PFS in first line group (HR: 1.85, 95% CI: 1.28-2.68), and low TLG group had a longer OS in undefined group (HR: 1.37, 95% CI: 1.00-1.86). No significant differences were in other subgroup analysis. CONCLUSION: Baseline MTV and TLG may have predictive value and should be prospectively studied in clinical trials. Baseline SUV(max) and SUV(mean) may not be appropriate prognostic markers in advanced or metastatic NSCLC patients treated with ICIs. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=323906, identifier CRD42022323906. |
format | Online Article Text |
id | pubmed-9713836 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97138362022-12-02 Prognostic value of (18)F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis Ling, Tao Zhang, Lianghui Peng, Rui Yue, Chao Huang, Lingli Front Immunol Immunology PURPOSE: This study aimed to investigate the value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in predicting early immunotherapy response of immune checkpoint inhibitors (ICIs) in patients with advanced or metastatic non-small-cell lung cancer (NSCLC). METHODS: A comprehensive search of PubMed, Web of science, Embase and the Cochrane library was performed to examine the prognostic value of (18)F-FDG PET/CT in predicting early immunotherapy response of ICIs in patients with NSCLC. The main outcomes for evaluation were overall survival (OS) and progression-free survival (PFS). Detailed data from each study were extracted and analyzed using STATA 14.0 software. RESULTS: 13 eligible articles were included in this systematic review. Compared to baseline (18)F-FDG PET/CT imaging, the pooled hazard ratios (HR) of maximum and mean standardized uptake values SUV(max), SUV(mean), MTV and TLG for OS were 0.88 (95% CI: 0.69-1.12), 0.79 (95% CI: 0.50-1.27), 2.10 (95% CI: 1.57-2.82) and 1.58 (95% CI: 1.03-2.44), respectively. The pooled HR of SUV(max), SUV(mean), MTV and TLG for PFS were 1.06 (95% CI: 0.68–1.65), 0.66 (95% CI: 0.48-0.90), 1.50 (95% CI: 1.26-1.79), 1.27 (95% CI: 0.92-1.77), respectively. Subgroup analysis showed that high MTV group had shorter OS than low MTV group in both first line group (HR: 1.97, 95% CI: 1.39-2.79) and undefined line group (HR: 2.11, 95% CI: 1.61-2.77). High MTV group also showed a shorter PFS in first line group (HR: 1.85, 95% CI: 1.28-2.68), and low TLG group had a longer OS in undefined group (HR: 1.37, 95% CI: 1.00-1.86). No significant differences were in other subgroup analysis. CONCLUSION: Baseline MTV and TLG may have predictive value and should be prospectively studied in clinical trials. Baseline SUV(max) and SUV(mean) may not be appropriate prognostic markers in advanced or metastatic NSCLC patients treated with ICIs. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=323906, identifier CRD42022323906. Frontiers Media S.A. 2022-11-17 /pmc/articles/PMC9713836/ /pubmed/36466905 http://dx.doi.org/10.3389/fimmu.2022.1014063 Text en Copyright © 2022 Ling, Zhang, Peng, Yue and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Ling, Tao Zhang, Lianghui Peng, Rui Yue, Chao Huang, Lingli Prognostic value of (18)F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis |
title | Prognostic value of (18)F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis |
title_full | Prognostic value of (18)F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis |
title_fullStr | Prognostic value of (18)F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis |
title_full_unstemmed | Prognostic value of (18)F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis |
title_short | Prognostic value of (18)F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis |
title_sort | prognostic value of (18)f-fdg pet/ct in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713836/ https://www.ncbi.nlm.nih.gov/pubmed/36466905 http://dx.doi.org/10.3389/fimmu.2022.1014063 |
work_keys_str_mv | AT lingtao prognosticvalueof18ffdgpetctinpatientswithadvancedormetastaticnonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT zhanglianghui prognosticvalueof18ffdgpetctinpatientswithadvancedormetastaticnonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT pengrui prognosticvalueof18ffdgpetctinpatientswithadvancedormetastaticnonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT yuechao prognosticvalueof18ffdgpetctinpatientswithadvancedormetastaticnonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis AT huanglingli prognosticvalueof18ffdgpetctinpatientswithadvancedormetastaticnonsmallcelllungcancertreatedwithimmunecheckpointinhibitorsasystematicreviewandmetaanalysis |